Program
efanesoctocog alfa
Also written as “Efanesoctocog alfa”, “efanesoctocog alfa (BIVV001)” and “BIVV001 (Low Dose)”.
Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.
Drug pageEfanesoctocog alfa: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 72 open or running | phase 4since Apr 16, 2025 | Jun 29, 2017 | Jan 15, 2027phase 3 · NCT04644575 |
| Swedish Orphan Biovitrum | 53 open or running | phase 4since Dec 18, 2024 | Mar 21, 2023 | Mar 2027phase 3 · NCT06716814 |
Also a collaborator on its studies: PSI CRO.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Swedish Orphan Biovitrum only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named efanesoctocog alfaINNProposed as its International Nonproprietary Name in WHO's List 122
- Mar 21, 2023First study: phase 3 study in Hemophilia AFirst studyNCT05817812 · 93 enrolled · Austria, Croatia, Czechia and more
- Aug 28, 2024Phase 1 study in Hemophilia ANCT06579144 · 24 enrolled · Bulgaria, Germany, Italy and more
- Oct 2, 2024Phase 3 study in Hemophilia ANCT06716814 · 89 enrolled · Bulgaria, France, Greece and more
- Dec 18, 2024Phase 4 study in Hemophilia ANCT06752850 · 37 enrolled · Italy, Norway, Spain and more
- Apr 16, 2025Phase 4 study in Hemophilia ANCT06940830 · 252 enrolled · Croatia, Czechia, France and more
Ahead
- Nov 17, 2026Primary completion: phase 4 study in Hemophilia ANCT06752850
- Mar 2027Primary completion: phase 3 study in Hemophilia ANCT06716814
- Dec 2028Primary completion: phase 4 study in Hemophilia ANCT06940830
TargetBeta
“A recombinant fusion protein comprising a single chain B-domain deleted (BDD) analog of human antihemophilic factor (coagulation factor VIII; FVIII) covalently ”NCIt, by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule
Other programs on F8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| antihemophilic factor, human recombinantrule | Takeda | phase 4 | 16 |
| omfiloctocog alfarule | Sinocelltech Group | phase 4 | 6 |
| lonoctocog alfarule | CSL | phase 3 | 4 |
Studies
All 5 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06940830Hemophilia A · Croatia, Czechia, France and more | 4 | Active, not recruiting | Dec 2028 | 252 |
| NCT06752850Hemophilia A · Italy, Norway, Spain and more | 4 | Active, not recruiting | Nov 17, 2026 | 37 |
| NCT06716814Hemophilia A · Bulgaria, France, Greece and more | 3 | Active, not recruiting | Mar 2027 | 89 |
| NCT06579144Hemophilia A · Bulgaria, Germany, Italy and more | 1 | Completed | May 21, 2026 | 24 |
| NCT05817812Hemophilia A · Austria, Croatia, Czechia and more | 3 | Completed | Jun 2, 2026 | 93 |
How it is read
Names in the registry
- “Efanesoctocog alfa”, 7 entries
- “efanesoctocog alfa (BIVV001)”, 4 entries
- “BIVV001 (Low Dose)”, 1 entry
- “BIVV001 (High Dose)”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 11 studies
- von Willebrand Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.